Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsAntonio Omuro, MD
Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Professor Adjunct
Biography
Dr. Omuro is a Professor Adjunct in the department of Neurology at the Yale School of Medicine.
He is the former chief of the Division of Neuro-Oncology and Director of the Yale Brain Tumor Center. He is a graduate and former faculty of the Neuro-Oncology program at Memorial Sloan Kettering Cancer Center in New York. Dr. Omuro is an internationally renowned leader in clinical care and research in the field of brain tumors, having led pivotal research projects and clinical trials to advance the treatment of these difficult cancers.
Dr. Omuro is currently the chair of the Department of Neurology and Neurological Sciences at Stanford University.
Last Updated on July 15, 2024.
Departments & Organizations
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2004)
- MD
- Sao Paulo School of Medicine (1995)
Research
Copy Link
Overview
Dr. Omuro is an international leader in the research of brain tumors, having led pivotal research programs and clinical trials to advance the treatment of these difficult cancers.
Medical Research Interests
Central Nervous System Neoplasms; Clinical Trial; Glioblastoma; Meningeal Neoplasms
ORCID
0000-0003-4299-3664
Research at a Glance
Yale Co-Authors
Frequent collaborators of Antonio Omuro's published research.
Publications Timeline
A big-picture view of Antonio Omuro's research output by year.
Research Interests
Research topics Antonio Omuro is interested in exploring.
Sanjay Aneja, MD
Mariam Aboian
Former YSMVeronica Chiang, MD, FAANS
MingDe Lin, PhD
Sara Merkaj
Alexandria Brackett, MLIS, AHIP, MA
162Publications
25,661Citations
Central Nervous System Neoplasms
Glioblastoma
Meningeal Neoplasms
Publications
2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).
Ellingson B, Cloughesy T, Ye X, Teraishi A, Raymond C, Oshima S, Sanvito F, Wen P, Walbert T, Campian J, Nabors L, Ozer B, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra R, Schiff D. Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801). American Journal Of Neuroradiology 2026, ajnr.a9438. PMID: 42217836, DOI: 10.3174/ajnr.a9438.Peer-Reviewed Original ResearchCERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas
Zhang S, Ozer B, Omuro A, Yuan Y, Mendoza T, Wall K, Grajkowska E, Vera E, Reyes J, Aldape K, Penas-Prado M, Wu J, Burton E, Walbert T, Mikkelsen T, Weathers S, O’Brien B, de Groot J, Puduvalli V, DeAngelis L, Pentsova E, Kaley T, Gavrilovic I, Gerstner E, Armstrong T, Gilbert M. CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas. Neuro-Oncology Advances 2026, 8: vdag016. PMID: 42016022, PMCID: PMC13092514, DOI: 10.1093/noajnl/vdag016.Peer-Reviewed Original ResearchChapter 41 Chemotherapy for primary central nervous system lymphoma
Therkelsen K, Omuro A. Chapter 41 Chemotherapy for primary central nervous system lymphoma. 2026, 675-692. DOI: 10.1016/b978-0-443-27356-8.00028-0.Books
2025
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
Schiff D, Ye X, Li J, Ellingson B, Wen P, Walbert T, Campian J, Nabors L, Ozer B, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra R. Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. Neuro-Oncology 2025, 28: 485-494. PMID: 41099363, PMCID: PMC12979031, DOI: 10.1093/neuonc/noaf246.Peer-Reviewed Original ResearchCitationsAltmetricMulticenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma
Omuro A, DeAngelis L, Polley M, Correa D, Wefel J, Bovi J, Rosenblum M, Corn B, Aneja S, Grommes C, Peereboom D, Lallana E, Werner-Wasik M, Rogers C, Iwamoto F, Yu H, Donnelly E, Struve T, Won M, Mehta M. Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro-Oncology 2025, 28: 371-382. PMID: 41189315, PMCID: PMC12904153, DOI: 10.1093/neuonc/noaf221.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Advances in Primary Central Nervous System Lymphoma
Therkelsen K, Omuro A. Advances in Primary Central Nervous System Lymphoma. Current Neurology And Neuroscience Reports 2024, 25: 5. PMID: 39585484, DOI: 10.1007/s11910-024-01389-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH KeywordsRadiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach
Wang D, Geng H, Gondi V, Lee N, Tsien C, Xia P, Chenevert T, Michalski J, Gilbert M, Le Q, Omuro A, Men K, Aldape K, Cao Y, Srinivasan A, Barani I, Sachdev S, Huang J, Choi S, Shi W, Battiste J, Wardak Z, Chan M, Mehta M, Xiao Y. Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach. Cancers 2024, 16: 2007. PMID: 38893130, PMCID: PMC11171017, DOI: 10.3390/cancers16112007.Peer-Reviewed Original ResearchCitationsAltmetricEnhancing clinical decision-making: An externally validated machine learning model for predicting isocitrate dehydrogenase mutation in gliomas using radiomics from presurgical magnetic resonance imaging
Lost J, Ashraf N, Jekel L, von Reppert M, Tillmanns N, Willms K, Merkaj S, Petersen G, Avesta A, Ramakrishnan D, Omuro A, Nabavizadeh A, Bakas S, Bousabarah K, Lin M, Aneja S, Sabel M, Aboian M. Enhancing clinical decision-making: An externally validated machine learning model for predicting isocitrate dehydrogenase mutation in gliomas using radiomics from presurgical magnetic resonance imaging. Neuro-Oncology Advances 2024, 6: vdae157. PMID: 39659829, PMCID: PMC11630777, DOI: 10.1093/noajnl/vdae157.Peer-Reviewed Original ResearchCitationsAltmetric
2023
Imaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original ResearchThe Yale Glioma Dataset: Developing An Open Access, Annotated MRI Database
Sala M, Lost J, Tillmanns N, Merkaj S, von Reppert M, Ramakrishnan D, Bousabarah K, Huttner A, Aneja S, Avesta A, Omuro A, Aboian M. The Yale Glioma Dataset: Developing An Open Access, Annotated MRI Database. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/4511.Peer-Reviewed Original Research
News
Copy Link
Get In Touch
Copy Link